Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines-Reference-Cited by-同舟云学术

Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines

Published:2021-01-19 Issue:3 Volume:325 Page:221
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Joffe Steven¹

Affiliation:

1. Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2774383/jama_joffe_2020_vp_200254_1610652660.60892.pdf

Reference10 articles.

1. Placebo-controlled trials of Covid-19 vaccines—why we still need them.;WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation;N Engl J Med,2020

2. Regulatory decision-making on COVID-19 vaccines during a public health emergency.;Avorn;JAMA,2020

3. Placebo-controlled trials and active-control trials in the evaluation of new treatments, part 1: ethical and scientific issues.;Temple;Ann Intern Med,2000

4. Optimizing the trade-off between learning and doing in a pandemic.;Angus;JAMA,2020

5. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 Corticosteroid Domain randomized clinical trial.;Angus;JAMA,2020

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phosphorothioate RNA Analysis by NETD Tandem Mass Spectrometry;Molecular & Cellular Proteomics;2024-04

2. Effect of coronavirus disease 2019 on the vaccine development paradigm;Exploration of Immunology;2023-10-10

3. A review on biotechnologically derived techniques to combat COVID-19 situation;Health Sciences Review;2023-09

4. Concern about the Effectiveness of mRNA Vaccination Technology and Its Long-Term Safety: Potential Interference on miRNA Machinery;International Journal of Molecular Sciences;2023-01-11

5. Equine immunoglobulin fragment F(ab’)2 displays high neutralizing capability against multiple SARS-CoV-2 variants;Clinical Immunology;2022-04